CA2593122A1 - Anti a beta antibody formulation - Google Patents
Anti a beta antibody formulation Download PDFInfo
- Publication number
- CA2593122A1 CA2593122A1 CA002593122A CA2593122A CA2593122A1 CA 2593122 A1 CA2593122 A1 CA 2593122A1 CA 002593122 A CA002593122 A CA 002593122A CA 2593122 A CA2593122 A CA 2593122A CA 2593122 A1 CA2593122 A1 CA 2593122A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- formulation
- beta
- humanized
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
The present invention provides formulations for maintaining the stability of A.beta. binding polypeptides, for example, A.beta. antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.
Claims (86)
1. A stabilized formulation comprising at least one A.beta. binding polypeptide, at least one tonicity agent, wherein the tonicity agent is present in an amount sufficient to render the formulation suitable for administration, and at least one buffering agent in an amount sufficient to maintain a physiologically suitable pH.
2. The formulation of claim 1, further comprising at least one antioxidant.
3. The formulation of claim 2, wherein at least one antioxidant is methionine.
4. The formulation of claim 1, wherein at least one tonicity agent is mannitol.
5. The formulation of claim 4, wherein at least one tonicity agent is NaCl.
6. The formulation of claim 1, wherein at least one buffering agent is histidine.
7. The formulation of claim 1, wherein at least one buffering agent is succinate.
8. The formulation of claim 1, wherein at least one buffering agent is sodium phosphate.
9. The formulation of claim 1, further coinprising at least one stabilizer.
10. The formulation of claim 9, wherein at least one stabilizer is polysorbate 80.
11. The formulation of claim 1, wherein at least one A.beta. binding polypeptide is selected from the group consisting of an anti A.beta. antibody, an anti A.beta. antibody Fv fragment, an anti A.beta. antibody Fab fragment, an anti A.beta. antibody Fab'(2) fragment, an anti A.beta. antibody Fd fragment, a single-chain anti A.beta.
antibody (scFv), a single domain anti A.beta. antibody fragment (Dab), a beta-pleated sheet polypeptide comprising at least one antibody complementarity determining region (CDR) from an anti A.beta. antibody, and a non-globular polypeptide comprising at least one antibody CDR from an anti A.beta. antibody.
antibody (scFv), a single domain anti A.beta. antibody fragment (Dab), a beta-pleated sheet polypeptide comprising at least one antibody complementarity determining region (CDR) from an anti A.beta. antibody, and a non-globular polypeptide comprising at least one antibody CDR from an anti A.beta. antibody.
12. The formulation of claim 11, wherein at least one A.beta. binding polypeptide is an anti A.beta. antibody.
13. The formulation of claim 12, wherein the anti A.beta. antibody specifically binds to an epitope within residues selected from the group consisting of 1-7, 1-5, 3-7, 3-6, 13-28, 15-24, 16-24, 16-21, 19-22, 33-40, and 33-42 of A.beta..
14. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 1-7.
15. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 1-5.
16. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 3-6.
17. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 3-7.
18. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 13-28.
19. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 16-24.
20. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 16-21.
21. The formulation of claim 13, wherein the anti A.beta. antibody specifically binds to an epitope within residues 19-22.
22. The formulation of claim 12, wherein the anti A.beta. antibody is selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, a humanized 266 antibody, a humanized 12A11 antibody, and a humanized 15C11 antibody.
23. The formulation of claim 22, further comprising a stabilizer and an antioxidant.
24. The formulation of claim 23, wherein the stabilizer is polysorbate 80, the antioxidant is methionine, the tonicity agent is mannitol, sorbitol or NaC1, and the buffering agent is histidine.
25. The formulation of claim 22, wherein the formulation is a lyophilized formulation.
26. The formulation of claim 22, wherein the formulation is a liquid formulation.
27. The formulation of claim 22, wherein the antibody is of isotype human IgG1.
28. The formulation of claim 22, wherein the antibody is of isotype human IgG4.
29. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 0.1 mg/ml to about 60 mg/ml.
30. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 20 mg/ml.
31. The formulation of claim 12, wherein the anti A.beta. antibody is present at a concentration of about 10 mg/ml.
32. The formulation of claim 23, wherein at least one tonicity agent is D-mannitol at a concentration of about 1% w/v to about 10% w/v.
33. The formulation of claim 32, wherein the concentration of D-mannitol is about 2% w/v to about 6% w/v.
34. The formulation of claim 23, wherein at least one buffering agent is histidine at a concentration of about 0.1 mM to about 25 mM.
35. The formulation of claim 23, wherein the formulation has a pH of about 5.5 to about 6.5.
36. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 3D6 antibody.
37. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 12A11 antibody.
38. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 266 antibody.
39. The formulation of claim 22, wherein the anti A.beta. antibody is a humanized 15C11 antibody.
40. A formulation stable for at least about 12 months at a temperature of above freezing to about 10°C and having a pH of about 5.5 to about 6.5, comprising:
i. at least one A.beta. antibody at a concentration of about 1 mg/ml to about 30 mg/ml;
ii. mannitol at a concentration of about 4% w/v or NaCl at a concentration of about 150 mM;
iii. about 5 mM to about 10 mM histidine or succinate; and iv. 10 mM methionine.
i. at least one A.beta. antibody at a concentration of about 1 mg/ml to about 30 mg/ml;
ii. mannitol at a concentration of about 4% w/v or NaCl at a concentration of about 150 mM;
iii. about 5 mM to about 10 mM histidine or succinate; and iv. 10 mM methionine.
41. The formulation of claim 40, wherein the formulation is stable for at least about 24 months at a temperature of about 2°C to 8°C, and comprises polysorbate 80 at a concentration of about 0.001 % w/v to about 0.01 % w/v.
42. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.5 and comprises about 10 mg/ml A.beta. antibody, about 10 mM histidine and about 4% w/v mannitol and about .005% w/v polysorbate 80.
43. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.2 and comprises about 20 mg/ml A.beta. antibody, about 10 mM
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
44. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to about 6.2 and comprises about 30 mg/ml A.beta. antibody, about 10 mM
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
histidine, about 4% w/v mannitol and about .005% w/v polysorbate 80.
45. The formulation of claim 40, wherein the A.beta. antibody is selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, a humanized 266 antibody, a humanized 12A11 antibody, and a humanized 15C11 antibody.
46. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 4% w/v mannitol and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 3D6 antibody, a humanized 10D5 antibody, a humanized 12B4 antibody, and a humanized 12A11 antibody.
47. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 150 mM NaCl and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 12B4 antibody, and a humanized 12A11 antibody.
48. The formulation of claim 40, wherein the formulation has a pH of about 6.0 to 6.5 and comprises about 10 mM histidine, about 4% w/v mannitol and about 2 mg/ml to about 20 mg/ml of an A.beta. antibody selected from the group consisting of a humanized 266 antibody and a humanized 15C11 antibody.
49. A formulation stable for at least about 24 months at a temperature of about 2°C
to about 8°C and having a pH of about 5.5 to about 6.5, comprising about 2 mg/ml to about 23 mg/ml of a humanized 3D6 antibody, about 10 mM histidine and about 10 mM methionine.
to about 8°C and having a pH of about 5.5 to about 6.5, comprising about 2 mg/ml to about 23 mg/ml of a humanized 3D6 antibody, about 10 mM histidine and about 10 mM methionine.
50. The formulation of claim 49, further comprising about 4% w/v mannitol.
51. The formulation of claim 49, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01 % w/v.
52. The formulation of claim 51, comprising about 0.005% w/v polysorbate 80.
53. The formulation of claim 49, wherein the humanized 3D6 antibody is present at a concentration of about 17 mg/ml to about 23 mg/ml.
54. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 5.5 to about 6.5, comprising about 2 mg/ml to about 23 mg/ml of a humanized 3D6 antibody, about 10 mM succinate, about 10 mM methionine, about 4% w/v mannitol and about 0.005% w/v polysorbate 80.
55. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 30 mg/ml of a humanized 266 antibody, about 10 mM histidine and about 10 mM methionine.
56. The formulation of claim 55, further comprising about 4% w/v mannitol.
57. The formulation of claim 55, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01% w/v.
58. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 30 mg/ml of a humanized 12A11 antibody, about 10 mM histidine and about mM methionine.
59. The formulation of claim 58, further comprising about 150 mM NaCl.
60. The formulation of claim 58, further comprising polysorbate 80 at a concentration of about 0.001% w/v to about 0.01% w/v.
61. A formulation stable for at least about 24 months at a temperature of about 2°C to about 8°C and having a pH of about 6.0 to about 6.5, comprising about 2 mg/ml to about 20 mg/ml of a humanized 12A11 antibody, about 5 mM histidine, about 10 mM methionine, about 4% w/v mannitol and about 0.005% w/v polysorbate 80.
62. A formulation stable when thawed from about -50°c to about -80°c, comprising about 40 to about 60 mg/ml of an anti A.beta. antibody, about 1.0 mg/ml to about 2.0 mg/ml histidine, about 1.0mg/ml to 2.0 mg/ml methionine and about 0.05 mg/ml polysorbate 80, wherein the formulation has a pH of about 6Ø
63. The formulation of claim 62, wherein mannitol is excluded.
64. The formulation of claim 63, wherein the A.beta. antibody is a humanized antibody.
65. The formulation of claim 63, wherein the A.beta. antibody is a humanized antibody.
66. A formulation comprising about 20 mg/mL anti A.beta. antibody, about 10 mM
L-histidine, about 10 mM methionine, about 4% mannitol and having a pH of about 6.
L-histidine, about 10 mM methionine, about 4% mannitol and having a pH of about 6.
67. A formulation comprising about 30 mg/mL anti A.beta. antibody, about 10 mM
succinate, about 10 mM methionine, about 6% mannitol and having a pH of about 6.2.
succinate, about 10 mM methionine, about 6% mannitol and having a pH of about 6.2.
68. A formulation comprising about 20 mg/mL anti A.beta. antibody, about 10 mM
L-histidine, about 10 mM methionine, about 4% mannitol, about 0.005% polysorbate 80, and having a pH of about 6.
L-histidine, about 10 mM methionine, about 4% mannitol, about 0.005% polysorbate 80, and having a pH of about 6.
69. A formulation comprising about 10 mg/mL anti A.beta. antibody, about 10 mM
succinate, about 10 mM methionine, about 10% mannitol, about 0.005%
polysorbate 80, and having a pH of about 6.5.
succinate, about 10 mM methionine, about 10% mannitol, about 0.005%
polysorbate 80, and having a pH of about 6.5.
70. A formulation comprising about 5 mg/mL to about 20 mg/mL anti A.beta.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 4%
mannitol, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 4%
mannitol, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
71. A formulation comprising about 5 mg/mL to about 20 mg/mL anti A.beta.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 150 mM
NaCl, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
antibody, about 5 mM to about 10 mM L-histidine, about 10 mM methionine, about 150 mM
NaCl, about 0.005% polysorbate 80, and having a pH of about 6.0 to about 6.5.
72. A pharmaceutical unit dosage form, comprising a formulation comprising:
a. about 10 mg to about 250 mg of an anti A.beta. antibody;
b. about 4% mannitol or about 150 mM NaCl;
c. about 5 mM to about 10 mM histidine or succinate; and d. about 10 mM methionine.
a. about 10 mg to about 250 mg of an anti A.beta. antibody;
b. about 4% mannitol or about 150 mM NaCl;
c. about 5 mM to about 10 mM histidine or succinate; and d. about 10 mM methionine.
73. The pharmaceutical unit dosage form of claim 72, comprising about 0.001%
to about 0.1% polysorbate 80.
to about 0.1% polysorbate 80.
74. The pharmaceutical unit dosage form of claim 73, comprising about 40 mg to about 60 mg of the anti A.beta. antibody.
75. The pharmaceutical unit dosage form of claim 73, comprising about 60 mg to about 80 mg of the anti A.beta. antibody.
76. The pharmaceutical unit dosage form of claim 73, comprising about 80 mg to about 120 mg of the anti A.beta. antibody.
77. The pharmaceutical unit dosage form of claim 73, comprising about 120 mg to about 160 mg of the anti A.beta. antibody.
78. The pharmaceutical unit dosage form of claim 73, comprising about 160 mg to about 240 mg of the anti A.beta. antibody.
79. A therapeutic product, comprising:
a. a glass vial, comprising a formulation comprising:
i. about 10 mg to about 250 mg of a humanized anti A.beta.
antibody, ii. about 4% mannitol or about 150 mM NaCl, iii. about 5 mM to about 10 mM histidine, and iv. about 10 mM methionine; and b. labeling for use comprising instructions to use the appropriate volume necessary to achieve a dose of about 0.15 mg/kg to about mg/kg.
a. a glass vial, comprising a formulation comprising:
i. about 10 mg to about 250 mg of a humanized anti A.beta.
antibody, ii. about 4% mannitol or about 150 mM NaCl, iii. about 5 mM to about 10 mM histidine, and iv. about 10 mM methionine; and b. labeling for use comprising instructions to use the appropriate volume necessary to achieve a dose of about 0.15 mg/kg to about mg/kg.
80. The therapeutic product of claim 79, wherein the dose is about .5 mg/kg to about 3 mg/kg.
81. The therapeutic product of claim 79, wherein the dose is about 1 mg/kg to about 2 mg/kg.
82. The therapeutic product of claim 79, wherein the anti A.beta. antibody concentration is about 10 mg/ml to about 60 mg/ml.
83. The therapeutic product of claim 79, wherein the anti A.beta. antibody concentration is about 20 mg/ml.
84. The therapeutic product of claim 79, further comprising about 0.005%
polysorbate 80.
polysorbate 80.
85. The therapeutic product of claim 79, wherein the use is a subcutaneous administration.
86. The therapeutic product of claim 79, wherein the use is an intravenous administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64863105P | 2005-01-28 | 2005-01-28 | |
US60/648,631 | 2005-01-28 | ||
PCT/US2006/002837 WO2006083689A2 (en) | 2005-01-28 | 2006-01-27 | Anti a beta antibody formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2593122A1 true CA2593122A1 (en) | 2006-08-10 |
CA2593122C CA2593122C (en) | 2012-03-06 |
Family
ID=36686080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2593122A Expired - Fee Related CA2593122C (en) | 2005-01-28 | 2006-01-27 | Anti a beta antibody formulation |
Country Status (30)
Country | Link |
---|---|
US (2) | US7635473B2 (en) |
EP (2) | EP1853310B1 (en) |
JP (1) | JP4977625B2 (en) |
KR (1) | KR101188060B1 (en) |
CN (2) | CN103768009B (en) |
AR (1) | AR052198A1 (en) |
AU (1) | AU2006211184B8 (en) |
BR (1) | BRPI0607039A2 (en) |
CA (1) | CA2593122C (en) |
DK (1) | DK1853310T3 (en) |
DO (1) | DOP2006000021A (en) |
EA (2) | EA015147B1 (en) |
ES (1) | ES2391407T3 (en) |
GT (1) | GT200600031A (en) |
HK (3) | HK1108132A1 (en) |
IL (1) | IL184599A (en) |
JO (1) | JO2740B1 (en) |
MX (1) | MX2007009050A (en) |
MY (1) | MY177052A (en) |
NO (1) | NO20073305L (en) |
NZ (1) | NZ556393A (en) |
PE (1) | PE20060879A1 (en) |
PL (1) | PL1853310T3 (en) |
PT (1) | PT1853310E (en) |
SI (1) | SI1853310T1 (en) |
TW (1) | TWI398263B (en) |
UA (1) | UA87549C2 (en) |
UY (1) | UY29351A1 (en) |
WO (1) | WO2006083689A2 (en) |
ZA (1) | ZA200705710B (en) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
CA2414772C (en) * | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
CA2513722A1 (en) * | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US7807804B2 (en) * | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
AR052051A1 (en) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
CA2611815A1 (en) * | 2005-06-17 | 2006-12-28 | Elan Pharma International Limited | Methods of purifying anti a beta antibodies |
PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
WO2007064972A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
RU2015111675A (en) | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES |
CA2635692C (en) * | 2005-12-29 | 2013-06-18 | Centocor, Inc. | Human anti-il-23 antibodies, compositions, methods and uses |
KR101413615B1 (en) * | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | Improved antibody selective for human protofibrils and the use thereof |
WO2010044803A1 (en) * | 2008-10-17 | 2010-04-22 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
SG173385A1 (en) | 2006-07-14 | 2011-08-29 | Ac Immune S A Ch | Humanized antibody against amyloid beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CA2671968A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2008131298A2 (en) * | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
JP5889529B2 (en) * | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Treatment of amyloidogenic diseases |
WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
CN101998863B (en) * | 2007-10-05 | 2015-09-16 | 基因技术公司 | The purposes of anti-amyloid beta antibody in oculopathy |
ES2445590T3 (en) | 2007-10-05 | 2014-03-04 | Genentech, Inc. | Use of anti-beta amyloid antibody in eye diseases |
ES2612788T3 (en) * | 2007-10-05 | 2017-05-18 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of amyloidosis |
JO3076B1 (en) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
ES2499395T3 (en) | 2008-05-23 | 2014-09-29 | Siwa Corporation | Procedures to facilitate regeneration |
CN102123726A (en) * | 2008-06-12 | 2011-07-13 | 阿费里斯股份公司 | Compounds for treating symptoms associated with parkinson's disease |
AU2009291865A1 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
WO2011107507A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
NZ606357A (en) | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
PT2616090T (en) * | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
JO3400B1 (en) * | 2010-09-30 | 2019-10-20 | Ferring Bv | Pharmaceutical composition of carbetocin |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
EP2697369B1 (en) | 2011-03-25 | 2018-06-27 | F.Hoffmann-La Roche Ag | Novel protein purification methods |
EP3311834A1 (en) * | 2011-05-02 | 2018-04-25 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
UY34105A (en) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | STABLE LIQUID FORMULATION OF ETANERCEPT |
US20140302021A1 (en) | 2011-10-25 | 2014-10-09 | Onclave Therapeutics Limited | Antibody formulations and methods |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
WO2014068029A1 (en) | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
AR093297A1 (en) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND |
UA117466C2 (en) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
US20140314741A1 (en) * | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
TWI694836B (en) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | Antibody formulation |
MA53887A (en) | 2014-07-10 | 2021-10-27 | Bioarctic Ab | ENHANCED PROTOFIBRILL A-BETA BINDING ANTIBODY |
CA3093383A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US11034760B2 (en) * | 2015-05-07 | 2021-06-15 | Swedish Orphen Biovitrum AG | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers |
US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
AR104847A1 (en) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | FORMULATION OF ANTI-CGRP ANTIBODY |
CR20170562A (en) | 2015-06-24 | 2018-02-01 | Hoffmann La Roche | TRANSFERRINE ANTI-RECEIVER ANTIBODIES WITH DESIGNATED AFFINITY. |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
CA2997801A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
DK3337829T3 (en) | 2016-02-19 | 2020-02-17 | Siwa Corp | METHOD AND COMPOSITION OF TREATMENT OF CANCER, KILLING OF METASTATIC CANCER CELLS AND PREVENTION OF CANCER METASTASE BY USING ANTIBODIES AGAINST ADVANCED GLYCING END PRODUCTS (AGE) |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
JP2019518763A (en) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | Vaccines for use in the treatment of various diseases and disorders |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
CN110352201A (en) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | The subcutaneous administration of antibody drug conjugate for cancer therapy |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
MX2020001851A (en) * | 2017-08-22 | 2020-08-20 | Biogen Ma Inc | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies. |
HUE061510T2 (en) | 2017-08-22 | 2023-07-28 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
US20190083618A1 (en) * | 2017-09-19 | 2019-03-21 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
KR20210114989A (en) | 2019-02-18 | 2021-09-24 | 일라이 릴리 앤드 캄파니 | therapeutic antibody formulation |
MX2023000949A (en) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anti-abeta antibodies. |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2727112B2 (en) * | 1988-04-26 | 1998-03-11 | コニカ株式会社 | Stable peroxidase composition and stable antibody composition |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE151110T1 (en) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING SITES |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06508511A (en) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | Method for producing specific binding pair members |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
DE69233697T2 (en) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Process for the development of binding microproteins |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
JP2966592B2 (en) * | 1991-07-20 | 1999-10-25 | 萩原 義秀 | Stabilized human monoclonal antibody preparation |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5385887A (en) | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
JP2002514919A (en) | 1997-04-04 | 2002-05-21 | バイオサイト ダイアグノスティックス,インコーポレイテッド | Multivalent and polyclonal libraries |
WO1998056418A1 (en) | 1997-06-13 | 1998-12-17 | Genentech, Inc. | Stabilized antibody formulation |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
JP2002511385A (en) | 1997-12-03 | 2002-04-16 | ニューララブ リミテッド | Method for suppressing β-amyloid-related changes in Alzheimer's disease |
US20050059802A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US20050059591A1 (en) | 1998-04-07 | 2005-03-17 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7282570B2 (en) * | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
PT1409654E (en) | 1999-06-16 | 2008-11-25 | Boston Biomedical Res Inst | Immunological control of beta-amyloid levels in vivo |
IL147599A0 (en) | 1999-07-15 | 2002-08-14 | Genetics Inst | Formulations for il-11 |
IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
JP2003516929A (en) * | 2000-06-01 | 2003-05-20 | ニユーララブ・リミテツド | Prevention and treatment of amyloidogenic diseases |
PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US6916745B2 (en) * | 2003-05-20 | 2005-07-12 | Fairchild Semiconductor Corporation | Structure and method for forming a trench MOSFET having self-aligned features |
ES2312569T3 (en) | 2001-04-30 | 2009-03-01 | Eli Lilly And Company | HUMANIZED ANTIBODIES. |
EP2165714B1 (en) | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
JP4317010B2 (en) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | Stable lyophilized pharmaceutical formulation of IgG antibody |
WO2003016466A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
EP1519740A4 (en) | 2001-08-17 | 2005-11-09 | Lilly Co Eli | Rapid improvement of cognition in conditions related to a-beta |
CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
US20030171556A1 (en) | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2003293543A1 (en) * | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
CA2513722A1 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
HUE026000T2 (en) | 2003-12-17 | 2016-04-28 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
EP2336147B1 (en) | 2003-12-17 | 2014-04-30 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
EP1563794B1 (en) * | 2004-02-17 | 2007-04-25 | Tyco Healthcare Group Lp | Surgical stapling apparatus with locking mechanism |
US7807804B2 (en) | 2004-10-05 | 2010-10-05 | Wyeth Llc | Methods and compositions for improving recombinant protein production |
WO2006047670A2 (en) | 2004-10-26 | 2006-05-04 | Wyeth | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
US20060153772A1 (en) | 2004-12-15 | 2006-07-13 | Wyeth | Contextual fear conditioning for predicting immunotherapeutic efficacy |
EP1838854B1 (en) | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antibodies that recognize Beta Amyloid Peptide |
AR051800A1 (en) | 2004-12-15 | 2007-02-07 | Wyeth Corp | BETA ANTIBODIES USED TO IMPROVE COGNITION |
AR052051A1 (en) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION |
US20060240486A1 (en) | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
DOP2006000022A (en) | 2005-01-28 | 2006-08-15 | Wyeth Corp | STABILIZED LIQUID FORMULATIONS OF POLYPTIDES |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
CA2611815A1 (en) | 2005-06-17 | 2006-12-28 | Elan Pharma International Limited | Methods of purifying anti a beta antibodies |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
WO2008131298A2 (en) | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
JP5889529B2 (en) * | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Treatment of amyloidogenic diseases |
JO3076B1 (en) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
IT1395574B1 (en) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | DISTRIBUTION DEVICE |
-
2006
- 2006-01-26 GT GT200600031A patent/GT200600031A/en unknown
- 2006-01-27 AR ARP060100315A patent/AR052198A1/en not_active Application Discontinuation
- 2006-01-27 CA CA2593122A patent/CA2593122C/en not_active Expired - Fee Related
- 2006-01-27 AU AU2006211184A patent/AU2006211184B8/en not_active Ceased
- 2006-01-27 EP EP06719621A patent/EP1853310B1/en active Active
- 2006-01-27 ZA ZA200705710A patent/ZA200705710B/en unknown
- 2006-01-27 PL PL06719621T patent/PL1853310T3/en unknown
- 2006-01-27 ES ES06719621T patent/ES2391407T3/en active Active
- 2006-01-27 WO PCT/US2006/002837 patent/WO2006083689A2/en active Application Filing
- 2006-01-27 US US11/342,353 patent/US7635473B2/en active Active
- 2006-01-27 DO DO2006000021A patent/DOP2006000021A/en unknown
- 2006-01-27 BR BRPI0607039-6A patent/BRPI0607039A2/en not_active IP Right Cessation
- 2006-01-27 EP EP20110164194 patent/EP2392353A1/en not_active Withdrawn
- 2006-01-27 MY MYPI20060416A patent/MY177052A/en unknown
- 2006-01-27 PE PE2006000114A patent/PE20060879A1/en not_active Application Discontinuation
- 2006-01-27 CN CN201210172792.1A patent/CN103768009B/en not_active Expired - Fee Related
- 2006-01-27 SI SI200631442T patent/SI1853310T1/en unknown
- 2006-01-27 EA EA200701596A patent/EA015147B1/en not_active IP Right Cessation
- 2006-01-27 MX MX2007009050A patent/MX2007009050A/en active IP Right Grant
- 2006-01-27 JP JP2007553242A patent/JP4977625B2/en not_active Expired - Fee Related
- 2006-01-27 NZ NZ556393A patent/NZ556393A/en not_active IP Right Cessation
- 2006-01-27 CN CN2006800035305A patent/CN101262884B/en not_active Expired - Fee Related
- 2006-01-27 EA EA201100180A patent/EA021507B1/en not_active IP Right Cessation
- 2006-01-27 TW TW095103326A patent/TWI398263B/en not_active IP Right Cessation
- 2006-01-27 UA UAA200708609A patent/UA87549C2/en unknown
- 2006-01-27 UY UY29351A patent/UY29351A1/en not_active Application Discontinuation
- 2006-01-27 PT PT06719621T patent/PT1853310E/en unknown
- 2006-01-27 DK DK06719621.2T patent/DK1853310T3/en active
- 2006-01-27 KR KR1020077019596A patent/KR101188060B1/en not_active IP Right Cessation
- 2006-01-29 JO JO200629A patent/JO2740B1/en active
-
2007
- 2007-06-28 NO NO20073305A patent/NO20073305L/en not_active Application Discontinuation
- 2007-07-12 IL IL184599A patent/IL184599A/en not_active IP Right Cessation
-
2008
- 2008-02-28 HK HK08102210.2A patent/HK1108132A1/en not_active IP Right Cessation
- 2008-09-30 HK HK08110924.2A patent/HK1118723A1/en not_active IP Right Cessation
-
2009
- 2009-12-14 US US12/637,508 patent/US8318164B2/en not_active Expired - Fee Related
-
2014
- 2014-10-13 HK HK14110199.2A patent/HK1196570A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2593122A1 (en) | Anti a beta antibody formulation | |
EP2991678B1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
EP2331078B1 (en) | Lyophilized formulations of engineered anti-il-23p19 antibodies | |
US11873343B2 (en) | Pharmaceutical formulations comprising anti-RANKL antibodies and an aromatic amino acid comprising a phenyl or an indole | |
CN110869002A (en) | Stable formulations of programmed death receptor 1(PD-1) antibodies and methods of use thereof | |
EP3129047B1 (en) | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates | |
EP3618855A1 (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
RU2007124933A (en) | STABILIZED LIQUID POLYPEPTIDE COMPOSITIONS | |
JP2008528638A5 (en) | ||
EA031436B1 (en) | Aqueous pharmaceutical composition, pre-filled syringe comprising same and use of the composition in treating autoimmune diseases | |
EP4218814A2 (en) | Stabilized formulations containing anti-pcsk9 antibodies | |
WO2018204343A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
KR102385802B1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
JP6400595B2 (en) | Anti-HER2 antibody preparation | |
US20210205453A1 (en) | Csf-1r antibody formulation | |
US20200231698A1 (en) | Bispecific antibody formulation | |
US20150225479A1 (en) | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations | |
US20230174638A1 (en) | Formulations of anti-il-33 antibodies | |
WO2018179138A1 (en) | Antibody-containing liquid preparation | |
US20170137535A1 (en) | Anti-factor d antibody formulations | |
TW201836637A (en) | Liquid pharmaceutical agent comprising antibody characterized by realizing the stability of dimer formation inhibition and deamidation inhibition during long-term storage and being suitable for a wide range of antibody concentration | |
JP2023532203A (en) | Activin A antibody preparation and method of use thereof | |
KR20220028972A (en) | Stable Pharmaceutical Formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190128 |